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Currently,  there  is no  registered  treatment  for  infections  with emerging  zoonotic  coronaviruses  like
SARS-  and  MERS-coronavirus.  We  here  report  that  in  cultured  cells low-micromolar  concentrations  of
alisporivir,  a non-immunosuppressive  cyclosporin  A-analog,  inhibit  the  replication  of four  different  coro-vailable online 10 November 2016
naviruses,  including  MERS-  and  SARS-coronavirus.  Ribavirin  was  found  to further  potentiate  the antiviral
effect  of  alisporivir  in these  cell  culture-based  infection  models,  but this  combination  treatment  was
unable  to improve  the  outcome  of  SARS-CoV  infection  in a mouse  model.  Nevertheless,  our  data  provide
a  basis  to further  explore  the  potential  of  Cyp  inhibitors  as host-directed,  broad-spectrum  inhibitors  of
coronavirus  replication.
ublis©  2016  The  Authors.  P
. Main text
The outbreak of the Severe Acute Respiratory Syndrome-
oronavirus (SARS-CoV) in 2003 and the continuing circulation
f the Middle East respiratory syndrome-coronavirus (MERS-CoV;
ince 2012) have highlighted the potentially lethal consequences
f zoonotic coronavirus infections in humans. Approximately 8000
eople were infected during the SARS-CoV epidemic (∼10% mor-
ality; http://www.who.int/csr/sars/en/), while the global MERS
ally is now over 1800 laboratory-conﬁrmed cases, with a mor-
ality of about 35% (http://www.who.int/csr/disease/coronavirus
nfections/en/). In mid-2015, an air travel-related outbreak in
outh Korea (186 conﬁrmed cases, 36 deaths, and about 17,000
otentially exposed individuals quarantined) again illustrated the
ocioeconomic impact of this kind of emerging pathogen, also out-
ide regions in which the virus is endemic (http://www.who.int/
sr/don/07-july-2015-mers-korea/en/). The lack of effective meth-
ds to prevent or treat coronavirus infections in humans remains a
erious public health concern, especially given increasing evidence
hat SARS-like coronaviruses continue to circulate in bats and may
∗ Corresponding authors.
E-mail addresses: A.H.de Wilde@lumc.nl (A.H. de Wilde), E.J.Snijder@lumc.nl
E.J. Snijder).
1 Current address: Vaccine and Infectious Disease Organization - International
accine Centre (VIDO-InterVac), University of Saskatchewan, Saskatoon, Canada.
ttp://dx.doi.org/10.1016/j.virusres.2016.11.011
168-1702/© 2016 The Authors. Published by Elsevier B.V. This is an open access article uhed  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license
(http://creativecommons.org/licenses/by/4.0/).
have the potential to readily cross the species barrier and emerge
as human pathogens (Ge et al., 2013; Menachery et al., 2015).
Data from cell culture infection models (Chan et al., 2013a,
2013b; de Wilde et al., 2013b; Falzarano et al., 2013a; Kindler et al.,
2013; Zielecki et al., 2013) and experiments in rhesus macaques
(Falzarano et al., 2013b) and marmosets (Chan et al., 2015) sug-
gested that interferons (IFNs) are potent inhibitors of MERS–CoV
replication. The outcome of the clinical use of interferons was
variable, with some reports questioning the long-term survival
beneﬁts (Al-Tawﬁq et al., 2014; Omrani et al., 2014; Shalhoub et al.,
2015), whereas others suggested that further investigation is war-
ranted (Khalid et al., 2016), possibly in combination with the use
of lopinavir/ritonavir (Kim et al., 2015). Unfortunately, some of the
negative outcomes are confounded by the late-stage treatment of
critically-ill patients.
Since the development and registration of novel therapeu-
tic compounds is generally time consuming, the repurposing of
approved drugs offers one of the few shortcuts to establishing anti-
coronavirus therapy. Several FDA-approved compounds have been
reported to inhibit MERS-CoV and SARS-CoV replication in cell cul-
ture (de Wilde et al., 2014; Dyall et al., 2014; Hart et al., 2013),
but their efﬁcacy in animal models remains to be determined. Pre-
viously, the FDA-approved drug cyclosporin A (CsA) was shown to
inhibit the replication of a variety of viruses (reviewed in Nagy et al.,
2011), including coronaviruses (Carbajo-Lozoya et al., 2014; de
Wilde et al., 2013b, 2011; Kim and Lee, 2014; Pfefferle et al., 2011;
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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anaka et al., 2012). CsA targets members of the cyclophilin (Cyp)
amily, which are peptidyl-proline isomerases (PPIases) that act as
haperones in protein folding and function (Davis et al., 2010). Since
he immuno suppressive properties of CsA (Schreiber and Crabtree,
992) are an undesirable side-effect in the context of antiviral ther-
py, numerous non-immunosuppressive Cyp inhibitors have been
eveloped. Among these, alisporivir (ALV) showed increased sus-
ained viral response during treatment of chronic hepatitis C virus
HCV) infection in phase III clinical trials, when treatment with rib-
virin and pegylated interferon was combined with ALV (Buti et al.,
015; Flisiak et al., 2012; Pawlotsky et al., 2015; Zeuzem et al.,
015).
In this study, we have ﬁrst investigated whether ALV inhibits
ERS- and SARS-CoV replication in cell culture. We  employed pre-
iously described cell-culture based screening assays relying on
he rapid cytopathic effect (CPE) observed in coronavirus-infected
ells (de Wilde et al., 2013b, 2014). First, the viability of MERS-
oV-infected Vero cells (MOI 0.005) treated with increasing ALV
oncentrations was assessed at 3 days post infection (p.i.). We
ound that virus-induced CPE was prevented by ALV in a dose-
ependent manner (EC50 3.6 M;  Fig. 1A). A similar efﬁcacy was
bserved in MERS-CoV-infected Huh7 cells (MOI 0.005) (EC50
.4 M;  Fig. 1B). The toxicity of ALV treatment was assessed for
oth cell lines and CC50 values were found to be comparable and
–13 times higher than the observed EC50 values (26.4 and 43.8 M,
espectively; see Fig. 1A-B). ALV sensitivity was not restricted to
he original MERS-CoV isolate (EMC/2012; Zaki et al., 2012) as sim-
lar EC50 values of 1.5 and 3.0 M were determined when using
ERS-CoV strain N3/Jordan in Vero (MOI 0.05) and Huh7 cells
MOI 0.005), respectively (Fig. 1C-D). The potential of ALV to inhibit
ther betacoronaviruses was illustrated by the complete block of
ARS-CoV replication in VeroE6 cells. The SARS-CoV ﬁeld isolate
rankfurt-1 was inhibited with an EC50 of 8.3 M (CC50 in VeroE6
ells is >50 M;  Fig. 1E; de Wilde et al., 2014) and for the mouse-
dapted SARS-CoV strain MA-15 (MOI 0.05; kindly provided by
rof. Luis Enjuanes, National Center of Biotechnology (CNB-CSIC),
adrid, Spain) an EC50 of 1.3 M was determined. The EC50, CC50,
nd selectivity index (SI) values are summarized in Table 1.
We next established that ALV treatment also reduced the yield of
nfectious MERS-CoV progeny. Vero and Huh7 cells were infected
ith MERS-CoV (MOI 0.01) and treated with increasing but non-
ytotoxic ALV concentrations (for cell viability data, see Fig. 1;
rey lines) from 1 h post infection (p.i.) onward. Progeny virus
rom MERS-CoV-infected Vero cells was harvested at 48 h p.i. and
itrated by plaque assay, which revealed a ∼2 log reduction when
sing 6.3 M ALV (Fig. 2A). This effect was more pronounced in
uh7 cells, as a comparable decrease in progeny titer was already
bserved when using 3.1 M ALV (Fig. 2B). Similar results were
btained using fully differentiated primary human airway epithe-
ial (HAE) cells, of which the non-ciliated cells were shown to be
he primary target for MERS-CoV infection (Raj et al., 2013). First,
ir–liquid interface cultures derived from two donors were cul-
ured for 14 days on semi-permeable transwell membranes (van
etering et al., 2007). Next, these HAE cell cultures were pre-
reated for 16 h with 25 M ALV or 0.13% EtOH (vehicle control)
nd infected with MERS-CoV isolate EMC/2012 (MOI of 2; titer
etermined on Vero cells). After a 48-h ALV treatment, MERS-CoV
rogeny titers were reduced by 1 or 3 log, depending on the donor
Fig. 2C-D).
In a second laboratory, the ability of ALV to inhibit MERS-CoV
eplication was assessed independently in Vero, LLC-MK2, and
uh7 cells. Cells were inoculated with MERS-CoV (EMC/2012) at
n MOI  of 0.001 and medium containing between 0.625 and 20 M
f ALV was added at 1 h p.i. Supernatant was collected on day 3
nd levels of infectious virus progeny assessed by TCID50 assay. In
arallel, toxicity was assessed using a cell viability assay. On day 3,earch 228 (2017) 7–13
a 4- to 5-log decrease in infectious progeny was  observed at a dose
of 10 M ALV and EC50 values of 3.9, 2.8, and 4.0 M were calcu-
lated for Vero, LLC-MK2, and Huh7 cells, respectively (Fig. S1 and
Table 1).
SARS-CoV infection (MOI 0.01) in Vero cells was sensitive to
3.1 M ALV (Fig. 2E), resulting in a near-complete block when
using 6.3 M ALV. A ∼1.5 log reduction in virus progeny could be
achieved in VeroE6 cells using the same dose (Fig. 2F), suggesting
that ALV treatment in VeroE6 cells was twice less effective com-
pared to Vero cells. For both SARS-CoV and MERS-CoV, differences
in ALV sensitivity in various cell lines were observed. One explana-
tion for such difference would be that ALV uptake differs per cell
line. Interestingly, we also observed remarkable difference in e.g.
SARS-CoV-induced cell death between VeroE6 and Vero cells, rang-
ing from severe CPE in the former to minimal CPE in the latter after
the same incubation period (unpublished observations). This sug-
gests that these related cell lines can respond quite differently to
virus infection.
To investigate the potential of ALV as a broad-spectrum coro-
navirus inhibitor, we  assessed the effect of ALV treatment on the
replication of two additional coronaviruses, murine hepatitis virus
(MHV; strain A59) and human coronavirus 229E (HCoV-229E). Fol-
lowing infection with an MOI  of 0.01, media were harvested at 16 h
p.i. for MHV  on 17Cl1 cells or 48 h p.i. for HCoV-229E on Huh7 cells
(Fig. 2G and H). When using an ALV dose of 6.3 M,  MHV  progeny
titers were decreased by 1 log, while a 25-M dose resulted in a ∼2-
log reduction without showing any signs of toxicity in uninfected
cells (cell viability values >85% of untreated 17Cl1 control cells were
observed for all ALV concentrations tested; data not shown). HCoV-
229E production was  reduced to a similar extent (∼1.5 and ∼2-log
reduction at 6.3 and 12.5 M ALV, respectively).
As ribavirin has previously been reported to inhibit MERS-CoV
replication (Falzarano et al., 2013a) and ALV and ribavirin have
been used together during clinical trials for hepatitis C treatment
(Pawlotsky et al., 2015), this combination was  tested in LLC-MK2
cells. Combining ribavirin and ALV treatment primarily had an
additive effect on antiviral activity, with the exception of the com-
bination of 25 g/ml ribavirin and 5 M ALV, which had a synergy
value of 1.51 (Fig. 3A) as calculated using MacSynergy II (Prichard
and Shipman, 1990). Increasing concentrations of ribavirin gradu-
ally lowered the cell viability measured without affecting cellular
morphology when assessed microscopically (Fig. 3B).
The above ﬁndings suggested that a combination approach
might have a chance of success in animal models. Therefore, we
assessed whether similar inhibitory effects could be observed in
a mouse model. We  employed the mouse-adapted MA15 strain of
SARS-CoV (Roberts et al., 2007) and animals were treated daily with
ALV (60 mg/kg) and/or ribavirin (50 mg/kg). Unfortunately, treat-
ment with ALV alone did not enhance survival (data not shown) and
combined therapy with ALV and ribavirin did not prevent weight
loss (Fig. 4A) or enhance survival (Fig. 4B).
Since the ALV concentration required for SARS-CoV inhibition
in cell culture was >100-fold higher than that required for inhibi-
tion of HCV replication (Coelmont et al., 2010; Paeshuyse et al.,
2006; Puyang et al., 2010), the negative outcome of this animal
experiment may  not be too surprising. Nevertheless, the use of
Cyp inhibitors remains a promising and innovative antiviral strat-
egy. This class of drugs can potentially inhibit against broad range
of pathogenic viruses, including hepatitis B virus (Phillips et al.,
2015; EC50 of 4.1 M),  HCV (Coelmont et al., 2010; Paeshuyse
et al., 2006; Puyang et al., 2010; EC50 values between 0.02 and
0.23 M),  and human immunodeﬁciency virus 1 (Ptak et al., 2008;
EC50 values in the low-nanomolar range). We  previously reported
that also the replication of two arteriviruses, which are distantly
related to coronaviruses, can be blocked by the ALV-related non-
immunosuppressive CsA analog Debio-064 (de Wilde et al., 2013a).
A.H. de Wilde et al. / Virus Research 228 (2017) 7–13 9
Fig 1. MERS-CoV- and SARS-CoV-induced cell death is strongly reduced by low-micromolar concentrations of alisporivir. (a,c) Vero or (b,d) Huh7 cells in 96-well plates were
infected with (a,b) MERS-CoV EMC/2012 (MOI 0.005) or (c,d) MERS-CoV N3/Jordan (MOI 0.05 in Vero cells and MOI  0.005 in Huh7 cells) in the presence of 0–50 M ALV. (e,f)
Vero  E6 cells in 96-well plates were infected with (e) SARS-CoV isolate Frankfurt-1 (MOI 0.005) or (f) SARS-CoV strain MA-15 (MOI 0.05) in the presence of 0–50 M ALV.
Mock-infected cells that did not receive ALV or solvent were used as a reference for cell viability (their relative viability was set at 100 %). Cells were incubated for 3 days
with  the exception for MERS-CoV EMC/2012 in Huh7 cells (2 days) and cell viability was monitored using the CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay
(Promega). In addition, the (potential) toxicity of ALV treatment was  monitored in parallel in mock-infected cell cultures. Graphs show the results (average and SD) of a
representative experiment that was performed in quadruplicate. All virus-cell combinations were tested at least twice. Lines represent relative cell viability in the absence
of  infection (ALV toxicity control); bars represent relative cell viability after infection and ALV treatment.
10 A.H. de Wilde et al. / Virus Research 228 (2017) 7–13
Fig. 2. Alisporivir inhibits the yield of MERS-CoV, SARS-CoV, MHV, and HCoV-229E from infected cells. (a, b) MERS-CoV EMC/2012-infected (MOI 0.01) (a) Vero and (b) Huh7
cells  were treated with 3.1 or 6.3 M ALV (Vero) or 3.1 to 12.5 M ALV (Huh7) from 1 h p.i. onward. At 48 h p.i., virus titers in the culture medium were determined by
plaque  assays as described before (van den Worm et al., 2012). (c,d) HAE cells from two different donors were cultured on semi-permeable 12-well transwell membranes
for  14 weeks. About 16 h prior to infection, 25 M ALV, 0.13% EtOH, or medium was  added to the basal side of the cell layer. Subsequently, cells were apically infected with
MERS-CoV (MOI of 2; titer determined on Vero cells). After 48 h, virus release from the apical side of the cell layer was determined by harvesting the mucous ﬂuid and
subsequent plaque assay. (e, f) SARS-CoV-infected (e) Vero or (f) VeroE6 cells (MOI 0.01) were treated with various concentrations of ALV from 1 h p.i. onwards, and virus
titers  in the culture medium at 32 h p.i. were determined by plaque assay. (g) 17Cl1 cells infected with MHV-A59 (MOI 0.01) or (h) Huh7 cells infected with HCoV-229E
(MOI 0.01) were treated with ALV from 1 h p.i. onwards, and infectious progeny titers were determined at 16 h p.i. and 48 h p.i., respectively. The graphs show the results of
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qualling that present at the highest ALV concentration used. Two-sided Student’s t
irus  replication between EtOH-treated and ALV-treated samples (* p < 0.05; ** p < 0
Our study reveals that ALV is a broad-spectrum coronavirus
nhibitor in cell culture, as it inhibits the replication of both alpha-
nd betacoronaviruses (Figs. 1 and 2 and Carbajo-Lozoya et al.,
014). Further research is needed to elucidate the exact mech-
nism of action underlying ALV’s interference with coronavirus
eplication, as well as the involvement of Cyps in the coronavirus
eplication cycle. For HCV, ALV has been shown to disrupt func-
ional interactions between cyclophilin A (CypA) and viral proteins
nd/or RNA (Coelmont et al., 2010; Garcia-Rivera et al., 2012; Nag
t al., 2012). Interestingly, although ALV has a ∼4 times higher afﬁn-
ty for CypA compared to CsA (unpublished data), the EC50 values
or both inhibitors are similar, leaving the possibility that ALV and
ther Cyp inhibitors target CoV replication independently of CypA.In a previous study, a 4-log reduction in HCoV-NL63 virus
rogeny was reported upon treatment of infected CaCo-2 cells
ith 10 M ALV (EC50 0.8 M;  Carbajo-Lozoya et al., 2014). The include cells that remained untreated (“-“) or are treated with an amount of EtOH
Graphpad Prism 7 software) was  used to determine the signiﬁcance of inhibition of
*** p < 0.001; n.s. not signiﬁcant).
observed variations in EC50 values suggest that different coron-
aviruses may  not be equally sensitive to the drug, although they
may  also reﬂect differences in e.g. experimental design, Cyp expres-
sion levels, and/or ALV uptake or turnover in different cell lines. The
lack of ALV activity in the SARS-CoV animal model suggests that the
drug itself may  not be suited for the treatment of coronavirus infec-
tions. Nevertheless, Cyp inhibitors remain interesting leads for the
development of host-directed anti-coronavirus therapy, as well as
interesting tools to study the role of Cyps in coronavirus replication
in more detail.
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Table  1
Inhibition of SARS-CoV and MERS-CoV infection by ALV treatment.
Virus Strain Cell line EC50a (M) CC50 a (M) SIb Read-out
MERS-CoV EMC/2012 Vero 3.6 ± 1.1 26.4 ± 1.0 7.3 CPE-based assayc
3.9 ± 1.7 >20 >5.1 Virus yieldd,e
Huh7 3.4 ± 1.0 43.8 ± 1.0 12.9 CPE-based assay
2.8 ± 1.0 >20 >7.1 Virus yield
LLC-MK2 4.0 ± 1.1 14.3 ± 1.8 3.6 Virus yield
N3/Jordan Vero 3.0 ± 1.0 26.4 ± 1.0 8.8 CPE-based assay
Huh7 1.5 ± 1.0 43.8 ± 1.0 29.2 CPE-based assay
SARS-CoV Frankfurt-1 VeroE6 8.3 ± 1.0 >50 >6.0 CPE-based assay
MA-15 VeroE6 1.3 ± 0.05 >50 >38.5 CPE-based assay
Data are from two independent laboratories. EC50 and CC50 values were calculated as described previously (de Wilde et al., 2014; Falzarano et al., 2013a). The selectivity
index  (SI), the relative efﬁcacy of a compound in speciﬁcally inhibiting virus replication, was calculated as CC50/EC50. Statistical analyses were performed using the results
of  at least two independent experiments.
a EC50 and CC50 values are means (± SE) from a representative experiment (n = 4) that was repeated at least twice.
b SI: Selectivity index, calculated as CC50/EC50.
c Data is presented in Fig. 1.
d Virus yield is determined by TCID50 assay (data is presented in Fig. S1; Falzarano et al., 2013a).
e Experiments performed to independently conﬁrm the antiviral effect of ALV in a second laboratory.
Fig. 3. Additive antiviral effects of combined Ribavirin and Alisporivir treatment
in  MERS-CoV-infected cell cultures. (a) LLC-MK2 cells infected with MERS-CoV at
an  MOI  of 0.001 were treated with a combination of 0.625 to 20 M ALV and 12.5
to  100 g/ml ribavirin from 1 h p.i. onwards. Virus titers in the culture medium
at  3 days p.i. were determined by TCID50 as previously described (Falzarano et al.,
2013a). (b) In parallel, control cells were treated with the same compound con-
centrations to determine cytotoxicity with a CellTiter 96 AQueous One solution cell
proliferation assay.
Fig. 4. Treatment with Ribavirin and alisporivir does not protect from SARS-CoV
infection in a mouse model. (a,b) Combination therapy with alisporivir and ribavirin
did not diminish morbidity (a) or mortality (b) in SARS-CoV MA15-infected mice.
Six-week-old BALB/c mice were infected with 40,000 PFU of SARS-CoV-MA15, and
then treated daily with 60 mg/kg alisporivir and 50 mg/kg ribavirin. Results of two
experiments combined, n = 10 for both groups.
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